Oceantech Acquisitions I — SPAC Merger (November 2023)
26 slides from Oceantech Acquisitions I's SPAC merger presentation, Nov 13, 2023
Slide 1: Investor Presentation November 2023
Investor Presentation November 2023
Slide 2: Disclaimer
Disclaimer These materials are not an offer to sell, and are not seeking an offer to buy, any securities of Regentis Biomaterials Ltd. (“Regentis” or the “Company”). This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these se
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements containe
Slide 4: Overview of OceanTech Acquisitions I Corp.
Overview of OceanTech Acquisitions I Corp. OTEC’s team has significant public company experience to support Regentis’ growth plans Decades of combined investing & operating experience Growth oriented investors & operators Robust M&A and capital markets experience Long-term track record of value crea
Slide 5: Corporate Highlights
Corporate Highlights Regentis Biomaterials is a regenerative medicine, clinical stage development company headquartered in Israel Large Market / Unmet Need • Current treatments for cartilage repair in the knee are unsatisfactory • Estimated US market of at least 400,000 procedures annually • No effe
Slide 6: Addressable Market
Addressable Market ~ 400,000 procedures annually (US) 980,000 arthroscopic knee procedures performed annually 60% (600,000) have cartilage damage 67% (400,000) are focal lesions Minimum Addressable market estimated at ~ 400,000 procedures annually (US) Sources : Health Advances LLC MACI market asses
Slide 7: GelrinC vs Competition in Cartilage Repair
GelrinC© vs Competition in Cartilage Repair Cell-based Products (Maci of Vericel) Pre-formed Bi-phasic plugs (AgiliC of Cartiheal) Resorbable Hydrogel Types of Lesions Limited Limited All Types Single Procedures Required Two surgeries : Biopsy + reimplantation Requires removal of healthy Bone tissue
Slide 8: GelrinC: A Novel Treatment for Cartilage Repair
GelrinC©: A Novel Treatment for Cartilage Repair GelrinC© is a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to focal articular knee cartilage. This cost-effective treatment offers orthopedic surgeons a simple to perform procedure while providing patients with susta
Slide 9: GelrinC Procedure and Mode of Action
GelrinCProcedure and Mode of Action 1. Stelar delivery device membrane covers cartilage lesion. Using a syringe GelrinC is introduced into the lesion. 2. Upon filing of the lesion, UV beam cures GelrinC into a soft rubbery implant. 3. As GelrinC implant recedes and resorbs, the cartilage lesion rim
Slide 10: Clinical Experience Overview
Clinical Experience Overview 10Clinical Pilot (Phase II) • Single arm • 55 subjects MFx Control Data • Phase III EU study using identical protocol Phase III (Pivotal) GelrinC • 80/120 patients -vs- Historical MFx Control • 60 patients • Allows data from Pilot to be statistically compared to Pivotal
Slide 11: GelrinC Procedure
| GelrinC Procedure = Regentis
Slide 12: The GelrinC Procedure
“The GelrinC procedure. Following standard microfracture , the stellar accessory is inserted through a small incision into the joint. After deployment, pressure is applied to seal the lesion. GelrinC is applied to completely fill the lesion. The acquiesce nature of GelrinC enables complete filling o
Slide 13: What makes GelrinC unique?
What makes GelrinC unique? 12
Slide 14: What Makes GelrinC unique?
“ What Makes GelrinC unique ?” Jason M. Scopp , M.D. Director, Joint preservation Center Peninsula Orthopedic Associates, P.A . “ GelrinC is unique in 3 different ways. The first is its liquid form, being liquid and then transitioning to a hydrogel allows it to form perfectly and match the anatomy o
Slide 15: How is GelrinC working for your patients?
How is GelrinC working for your patients? 13
Slide 16: How is GelrinC working for your patients?
“ How is GelrinC working for your patients ?” Jason M. Scopp , M.D. Director, Joint preservation Center Peninsula Orthopedic Associates, P.A . “I’ve been very pleased with the clinical outcomes of GelrinC with my patients. It reminds me of my first patient that I performed the procedure on. She was
Slide 17: EU Pilot (Phase II) Clinical Results
I GelrinC Procedure EU Pilot (Phase II) Clinical Results KOOS Pain Measurement – 4 Year Efficiency EU Clinical Pilot (Phase II) Results - Data demonstrated statistically significant improvement over microfracture • Safe - Low incidence of Adverse Events (equivalent to microfracture alone) • Effectiv
Slide 18: Conclusion from EU Clinical Pilot/Phase II
Conclusion from EU Clinical Pilot/Phase II Simple and Quick Procedure Quick Patient Recovery Outstanding Long-Term Efficacy Outcomes • 10 min implantation procedure • Suitable for a wide range of lesions • Recovery in as fast as 2 weeks(1) • Superior clinical outcome compared to microfracture • Clin
Slide 19: GelrinC Pivotal Trial Design
GelrinCPivotal Trial Design • FDA allowed the company the use of microfracture data, owned by the company, as historical control rendering the trial more efficient and less costly • GelrinC efficacy is compared to historical microfracture (the current “gold” standard) procedure • Pivotal study requi
Slide 20: GelrinC Pivotal Trial Design Advantages
GelrinCPivotal Trial Design Advantages Precedent setting study design: GelrinC compared to historical microfracture data • Advantages include o Fewer study patients + easier enrollment o Microfracture results already known ⇒ No control arm variability • Same protocol as in pilot so results are expec
Slide 21: Expected Value Drivers and Milestones
Expected Value Drivers and Milestones 18Estimated to complete clinical pivotal trial and file PMA within 2.5 years Estimated to start marketing with potential European partner within one year 18
Slide 22: Comprehensive Intellectual Property
Comprehensive Intellectual Property 1946 • Issued patents 11 • U.S. patents 34 • Foreign patents 8 • Pending patent applications 28 • Foreign patents being nationally validated in certain European extension/validation states (1)Data compiled from S-4/A filed on 9/13/2023 19
Slide 23: Experienced Management Team
Experienced Management Team Ehud Geller, PhD, MBA Executive Chairman ▪ Former President & CEO of Interpharm Laboratories and EVP of Teva Group ▪ Former head of the Israeli Pharmaceutical Manufacturers Association and board member of the Tel Aviv Stock Exchange ▪ National Industry award for contribut
Slide 24: Board of Directors
Board of Directors(1) Ehud Geller, PhD, MBA Executive Chairman • Former President & CEO of Interpharm Laboratories and EVP of Teva Group • Former head of the Israeli Pharmaceutical Manufacturers Association and board member of the Tel Aviv Stock Exchange • National Industry award for contribution to
Slide 25: Summary Transaction Overview
Summary Transaction Overview Overview • The combined company will be known as Regentis Biomaterials Corp. • Will operate under the same management team as Regentis Biomaterials LTD • Anticipated closing in Q4 2023 Ownership Financing Transaction Rationale Use of Proceeds • The transaction contemplat
Slide 26: Thank you!
Thank you! REGENTIS BIOMATERIALS LTD. 12 Ha’ilan Street Northern Industrial Zone, P.O. Box 260 Or-Akiva 306000, Israel Tel: +972 9 960 1917 This Investor Presentation is filed by OceanTech Acquisitions I Corp., a Delaware corporation (the “ Company ” or “ OceanTech ”), together with R.B. Merger Sub
OceanTech Acquisitions I — SPAC Merger (November 2023) on 6ix